Desperate times: phage cocktail takes on Drug-Resistant lung bug
NCT ID NCT07429162
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a special cocktail of viruses (phages) designed to attack a drug-resistant bacterium causing chronic lung infection. Only one person will receive the treatment alongside their usual antibiotics. The goal is to see if it's safe and can reduce the amount of bacteria in the lungs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DP-QB-MYA-002 (a cocktail of viruses that attack bacteria, called phages)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat lung infections that don't respond to standard antibiotics.
- What could go wrong
- This is a very early phase 1 trial with only 1 participant, so results may not apply to others. The phage therapy may not reduce the infection or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIOPHAGE THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug candidate takes on stubborn lung infection
- Massive rural health study aims to uncover heart and lung disease risks
- Biobank aims to unlock secrets of phage therapy against superbugs
- Viruses vs. superbugs: new hope for skin infections?
- New hope against Drug-Resistant lung infection?
- 500 asthma patients enrolled in landmark biologic registry